Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Yearbook of Oncology ◽

10.1016/j.yonc.2012.08.022 ◽

2012 ◽

Vol 2012 ◽

pp. 30-31 ◽

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Her2 Positive ◽

Phase 3 ◽

Multicentre Phase

Download Full-text

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

10.1016/s0140-6736(11)61847-3 ◽

2012 ◽

Vol 379 (9816) ◽

pp. 633-640 ◽

Author(s):

José Baselga ◽

Ian Bradbury ◽

Holger Eidtmann ◽

Serena Di Cosimo ◽

Evandro de Azambuja ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Her2 Positive ◽

Phase 3 ◽

Multicentre Phase

Download Full-text

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

The Lancet Oncology ◽

10.1016/s1470-2045(14)70320-1 ◽

2014 ◽

Vol 15 (10) ◽

pp. 1137-1146 ◽

Author(s):

Evandro de Azambuja ◽

Andrew P Holmes ◽

Martine Piccart-Gebhart ◽

Eileen Holmes ◽

Serena Di Cosimo ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Pathological Complete Response ◽

Complete Response ◽

Survival Outcomes ◽

Her2 Positive ◽

Phase 3 ◽

Multicentre Phase

Download Full-text

46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study

Annals of Oncology ◽

10.1016/j.annonc.2021.03.060 ◽

2021 ◽

Vol 32 ◽

pp. S40-S41

Author(s):

S-A. Im ◽

A.R. Tan ◽

A. Mattar ◽

R. Colomer ◽

D. Stroyakovskii ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Injection ◽

Fixed Dose Combination ◽

Phase Iii ◽

Her2 Positive ◽

Multicentre Phase ◽

Dose Combination

Download Full-text

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30716-7 ◽

2018 ◽

Vol 19 (1) ◽

pp. 115-126 ◽

Author(s):

Sara A Hurvitz ◽

Miguel Martin ◽

W Fraser Symmans ◽

Kyung Hae Jung ◽

Chiun-Sheng Huang ◽

...

Keyword(s):

Breast Cancer ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3 ◽

Multicentre Phase ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies

Annals of Oncology ◽

10.1093/annonc/mdw364.66 ◽

2016 ◽

Vol 27 ◽

pp. vi63

Author(s):

X. Pivot ◽

C. Poole ◽

M. Martín ◽

J. Gligorov ◽

C.H. Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Early Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Multicentre Phase ◽

Download Full-text

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(20)30536-2 ◽

2021 ◽

Vol 22 (1) ◽

pp. 85-97 ◽

Author(s):

Antoinette R Tan ◽

Seock-Ah Im ◽

André Mattar ◽

Ramon Colomer ◽

Daniil Stroyakovskii ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Injection ◽

Fixed Dose Combination ◽

Her2 Positive ◽

Phase 3 ◽

Dose Combination

Download Full-text

Faculty Opinions recommendation of Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955064.793462779 ◽

2012 ◽

Author(s):

Nancy Lin ◽

Ines Vaz-Luis

Keyword(s):

Breast Cancer ◽

Intravenous Administration ◽

Clinical Stage ◽

Randomised Trial ◽

Stage I ◽

Her2 Positive ◽

Phase 3 ◽

Adjuvant Trastuzumab

Download Full-text

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30702-6 ◽

2021 ◽

Vol 22 (3) ◽

pp. 351-360

Author(s):

Binghe Xu ◽

Min Yan ◽

Fei Ma ◽

Xichun Hu ◽

Jifeng Feng ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Phase 3 ◽

Randomised Controlled

Download Full-text

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00122-4 ◽

2021 ◽

Author(s):

José Manuel Pérez-García ◽

Geraldine Gebhart ◽

Manuel Ruiz Borrego ◽

Agostina Stradella ◽

Begoña Bermejo ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Fdg Pet ◽

Pathological Response ◽

Phase 2 ◽

Her2 Positive ◽

Phase 2 Trial ◽

Download Full-text

Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30419-9 ◽

2017 ◽

Vol 18 (9) ◽

pp. 1211-1220 ◽

Author(s):

Marloes G M Derks ◽

Erik J Blok ◽

Caroline Seynaeve ◽

Johan W R Nortier ◽

Elma Meershoek-Klein Kranenbarg ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Tamoxifen ◽

Phase 3 ◽

Download Full-text